Sumitomo Dainippon Pharma Co Ltd (4506.T)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|73||2018||Chairman of the Board, Representative Director|
|60||2018||President, Representative Director|
|60||2016||Managing Executive Officer, Chief Director of Sales, Director|
|2017||Managing Executive Officer, Chief Director of Production|
|2017||Managing Executive Officer|
- BRIEF-Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors
- BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement
- BRIEF-Sumitomo Dainippon Pharma says change of president
- BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement
- BRIEF-Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.